Xylazine Adulteration of the Heroin-Fentanyl Drug Supply : A Narrative Review
- PMID: 37812779
- DOI: 10.7326/M23-2001
Xylazine Adulteration of the Heroin-Fentanyl Drug Supply : A Narrative Review
Abstract
Xylazine is an animal sedative, approved by the U.S. Food and Drug Administration, that is commonly used in veterinary medicine and is not approved for human use. Since 2016, xylazine has consistently appeared in the illicitly manufactured fentanyl supply and has significantly increased in prevalence, likely due to its low cost, easy availability, and presumed synergistic psychoactive effect. Clinical experience along with the available pertinent research were used to review xylazine adulteration of the drug supply and provide guidance on the care of patients exposed to xylazine. This review discusses xylazine pharmacology, animal and human clinical effects, and what is known to date about care of patients experiencing acute overdose, xylazine-fentanyl withdrawal, and xylazine-associated wounds.
Conflict of interest statement
Similar articles
-
National Institute on Drug Abuse Clinical Trials Network Meeting Report: Managing Patients Exposed to Xylazine-Adulterated Opioids in Emergency, Hospital and Addiction Care Settings.Ann Emerg Med. 2024 Jul;84(1):20-28. doi: 10.1016/j.annemergmed.2024.01.041. Epub 2024 Mar 16. Ann Emerg Med. 2024. PMID: 38493376 Review.
-
Rapid Analysis of Drugs: A Pilot Surveillance System To Detect Changes in the Illicit Drug Supply To Guide Timely Harm Reduction Responses - Eight Syringe Services Programs, Maryland, November 2021-August 2022.MMWR Morb Mortal Wkly Rep. 2023 Apr 28;72(17):458-462. doi: 10.15585/mmwr.mm7217a2. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37104171
-
The first drug-related death associated with xylazine use in the UK and Europe.J Forensic Leg Med. 2023 Jul;97:102542. doi: 10.1016/j.jflm.2023.102542. Epub 2023 May 22. J Forensic Leg Med. 2023. PMID: 37236142
-
Xylazine: Pharmacology Review and Prevalence and Drug Combinations in Forensic Toxicology Casework.J Anal Toxicol. 2022 Oct 14;46(8):911-917. doi: 10.1093/jat/bkac049. J Anal Toxicol. 2022. PMID: 35770859
-
Pharmacology and toxicology of xylazine: quid novum?Eur Rev Med Pharmacol Sci. 2023 Aug;27(15):7337-7345. doi: 10.26355/eurrev_202308_33305. Eur Rev Med Pharmacol Sci. 2023. PMID: 37606142 Review.
Cited by
-
Présence de xylazine sur le marché illicite des opioïdes.CMAJ. 2024 May 12;196(18):E635-E636. doi: 10.1503/cmaj.231603-f. CMAJ. 2024. PMID: 38740412 Free PMC article. French. No abstract available.
-
Knowledge, Preference, and Adverse Effects of Xylazine Among Adults in Substance Use Treatment.JAMA Netw Open. 2024 Feb 5;7(2):e240572. doi: 10.1001/jamanetworkopen.2024.0572. JAMA Netw Open. 2024. PMID: 38416493 Free PMC article.
-
Xylazine co-occurrence with illicit fentanyl is a growing threat in the Deep South: a retrospective study of decedent data.Harm Reduct J. 2024 Feb 20;21(1):46. doi: 10.1186/s12954-024-00959-2. Harm Reduct J. 2024. PMID: 38378660 Free PMC article.
-
Xylazine in the illicit opioid supply.CMAJ. 2024 Feb 4;196(4):E133. doi: 10.1503/cmaj.231603. CMAJ. 2024. PMID: 38316456 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources